Priothera

Priothera is committed to pioneering innovative therapies that can enhance the curative potential of both allogeneic hematopoietic cell transplantation (allo-HCT) and CAR T cell therapy. Our goal is to deliver treatments that not only improve survival rates but also ensure safer and more effective long-term outcomes compared to today’s standard care.​ ​

Priothera is exploring ways to address unmet medical needs in hematological malignancies by investigating innovative immune modulators that can enhance outcomes in allogeneic hematopoietic cell transplantation. Through the development of our investigational drug, mocravimod, we aim to address critical challenges in current allo-HCT maintenance strategies by enhancing the graft-versus-leukemia (GvL) effect while simultaneously reducing graft-versus-host disease (GvHD)